SGSM1

SGSM1 (RUTBC2) is a RUN- and TBC-domain-containing regulator of small G protein signaling that operates within the trans-Golgi network/endosomal system to couple Rab9A effector function to Rab36/Rab34 inactivation (PMID:17509819, PMID:22637480). Endogenous SGSM1 localizes to the trans-Golgi network (PMID:17509819), where it binds Rab9A specifically as an effector without acting as a Rab9A GAP, while displaying its highest GTPase-activating activity toward Rab34 and Rab36 (PMID:22637480). Cellular assays establish a functional GAP role: wild-type SGSM1 reduces membrane-associated Rab36, whereas the catalytically inactive R829A mutant does not (PMID:22637480). SGSM1 protein levels are controlled post-translationally by TRIM21-mediated ubiquitination and degradation, an event antagonized by SHISA3, with consequences for MAPK pathway activation and nasopharyngeal carcinoma cell invasion (PMID:30573520).

1. 2007 Medium

   Established that SGSM1 is a candidate modulator of small G protein signaling by linking its RUN/TBC domain architecture to physical association with RAP and RAB subfamily GTPases.

   Evidence Co-immunoprecipitation after cDNA overexpression plus immunofluorescence

   PMID:17509819

   Open questions at the time

   • Co-IP from overexpression without in vitro reconstitution or mutagenesis
   • Did not distinguish effector binding from GAP activity
   • Specific Rab partners not resolved
2. 2007 Medium

   Placed SGSM1 at the trans-Golgi network, anchoring its candidate role in vesicular transport to a defined compartment.

   Evidence Immunofluorescence of endogenous protein in mouse Neuro2a cells

   PMID:17509819

   Open questions at the time

   • Single method, single cell line
   • No functional consequence of localization demonstrated
   • Membrane-targeting determinants unknown
3. 2012 High

   Resolved the dual molecular logic of SGSM1: it binds Rab9A as an effector without hydrolyzing its GTP, yet acts catalytically as a GAP preferentially toward Rab34 and Rab36, defining a substrate-versus-partner distinction.

   Evidence In vitro binding and RabGAP activity screening plus cell-based co-IP, with R829A catalytic mutant control

   PMID:22637480

   Open questions at the time

   • Physiological output of Rab9A binding not defined
   • Relative in vivo contribution of Rab34 vs Rab36 unresolved
   • No structural model of the Rab9A-SGSM1-Rab36 link
4. 2012 High

   Demonstrated that SGSM1 GAP activity is functional in cells by showing wild-type but not R829A SGSM1 depletes membrane-bound Rab36.

   Evidence Active-site mutagenesis with membrane fractionation/co-localization in cultured cells

   PMID:22637480

   Open questions at the time

   • Downstream trafficking consequence of Rab36 inactivation not traced
   • Cell-type generality untested
5. 2018 Medium

   Identified post-translational control of SGSM1 abundance, showing TRIM21 ubiquitinates and degrades it while SHISA3 stabilizes it, with downstream effects on MAPK signaling and tumor cell invasion.

   Evidence Reciprocal co-IP, ubiquitination assay, siRNA knockdown, and in vitro/in vivo invasion assays

   PMID:30573520

   Open questions at the time

   • Mechanistic link between SGSM1 GAP activity and MAPK regulation not established
   • Single lab
   • Ubiquitination site on SGSM1 not mapped

• How SGSM1 effector binding to Rab9A is mechanistically coupled to its GAP-driven inactivation of Rab36/Rab34, and how this trafficking activity connects to its TRIM21/SHISA3-regulated role in MAPK signaling, remains unresolved.
• No structural basis for simultaneous Rab9A binding and Rab36 GAP catalysis
• Causal chain from Rab36 inactivation to MAPK output undefined
• Endogenous loss-of-function trafficking phenotype not characterized